What medication regimen is recommended for a 21-year-old female with type 1 diabetes on Basaglar (insulin glargine) with an elevated Hemoglobin A1c (HbA1c) level?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medication Regimen for Type 1 Diabetes with Elevated A1c

For a 21-year-old female with type 1 diabetes currently on Basaglar (insulin glargine) with an A1c of 9.1%, a basal-bolus insulin regimen is strongly recommended to improve glycemic control and reduce risk of complications.

Current Assessment

  • 21-year-old female with type 1 diabetes
  • Currently on Basaglar (insulin glargine) only
  • A1c of 9.1% (significantly above target)
  • No prandial insulin coverage mentioned

Recommended Treatment Approach

Step 1: Optimize Basal Insulin

  • Continue Basaglar (insulin glargine)
  • Assess adequacy of current basal dose
  • Titrate to target fasting blood glucose
  • Consider clinical signs of overbasalization if dose exceeds ~0.5 units/kg/day 1

Step 2: Add Prandial Insulin (Critical Addition)

  • Add rapid-acting insulin analog before meals 1
  • Initial prandial dose: 4 units per meal or 10% of basal insulin dose 1
  • Titrate by increasing dose by 1-2 units or 10-15% twice weekly based on postprandial glucose readings 1
  • For hypoglycemia: determine cause; if no clear reason, lower corresponding dose by 10-20% 1

Step 3: Monitoring and Adjustment

  • Monitor blood glucose before meals and at bedtime
  • Target pre-meal glucose: 80-130 mg/dL
  • Target post-meal glucose: <180 mg/dL
  • Recheck A1c in 3 months 2
  • Adjust insulin doses based on patterns in blood glucose readings

Rationale for Recommendation

Type 1 diabetes requires both basal and prandial insulin coverage to effectively control blood glucose levels. The current regimen of Basaglar alone is insufficient, as evidenced by the elevated A1c of 9.1%.

The American Diabetes Association guidelines clearly indicate that patients with type 1 diabetes require a basal-bolus insulin regimen to properly manage their condition 1. This includes:

  1. Basal insulin (already on Basaglar)
  2. Prandial insulin with each meal (currently missing)

Studies have shown that a proper basal-bolus regimen can significantly improve glycemic control in patients with type 1 diabetes compared to basal insulin alone 3. The addition of prandial insulin is essential to address postprandial glucose excursions, which are a major contributor to elevated A1c levels.

Important Considerations

  • Hypoglycemia risk: Monitor closely when initiating prandial insulin and adjust doses as needed 4
  • Education: Ensure patient understands carbohydrate counting and insulin-to-carb ratios
  • Sick day management: Provide guidance on insulin adjustments during illness
  • Regular follow-up: Schedule frequent visits initially to adjust insulin doses

Alternative Considerations

While insulin pump therapy could be considered as an alternative to multiple daily injections, studies have shown no significant difference in glycemic control between properly managed basal-bolus regimens and insulin pump therapy 5. The decision to transition to pump therapy should be based on patient preference, lifestyle, and ability to manage the technology.

The most important intervention at this time is the addition of prandial insulin to the current basal insulin regimen to achieve target glycemic control and reduce the risk of long-term diabetes complications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diabetes Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control.

Journal of pediatric endocrinology & metabolism : JPEM, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.